Generational Differences? The Risk Of VTE With Oral Contraceptives
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Venous thromboembolism is a long-recognized risk of oral contraceptives, but there are concerns that later generations of progestins have heightened that risk.
You may also be interested in...
EMA Birth Control Safety Review Shows PRAC’s Clout, Concern About Newer Products
The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.